Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 65 (11), 699-703

Interferon-alpha in the Treatment of Myeloproliferative Diseases

  • PMID: 31906676

Interferon-alpha in the Treatment of Myeloproliferative Diseases

Jarmila Kissová. Vnitr Lek.

Abstract

Despite significant progress, the treatment options for myeloproliferative neoplasms (MPN) are still limited. Interferon α (IFNα) has been recognized as a substance for the treatment of MPN for more than 30 years, but its widespread use has been limited by higher frequency of short-term adverse reactions compared to conventional treatment and until recently, by its off-label indication in BCR/ABL negative MPNs. With the development of pegylated forms of IFNα with a more favorable toxicity and pharmacokinetic profile have renewed interest in the use of IFNα in the treatment of MPN. Recent studies confirm that IFNα is important drug capable of reducing the tumor population in MPN. Thus, IFNα is currently a more frequently considered drug in the treatment of MPN and has adop-ted into of some expert recom-mendations as a first-line drug for younger patients with various subtypes of MPN.

Keywords: essential thrombocythemia; interferon α; myeloproliferative neoplasm; pegylated interferon-α; polycythemia vera; primary myelofibrosis.

Similar articles

See all similar articles

MeSH terms

LinkOut - more resources

Feedback